Caractéristiques et déterminants de l’initiation d’un traitement progestatif oral dans la cohorte française E3N

Prentice, 1999, Fortnightly review. Medical management of menorrhagia, BMJ, 319, 1343, 10.1136/bmj.319.7221.1343 Wyatt, 2001, Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review, BMJ, 323, 776, 10.1136/bmj.323.7316.776 Lowy, 2005, French hormones: progestins and therapeutic variation in France, Soc Sci Med, 60, 2609, 10.1016/j.socscimed.2004.10.021 Plu-Bureau, 1994, Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease, Br J Cancer, 70, 270, 10.1038/bjc.1994.291 Lopes, 2005, Propause survey: profile of patients treated with progestins in perimenopause, J Gynecol Obstet Biol Reprod (Paris), 34, 232 Ringa, 2007, Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort, Maturitas, 58, 216, 10.1016/j.maturitas.2007.08.008 Jamin, 2008, Rationalizing progestin-only contraception (except IUS with levonorgestrel), Gynecol Obstet Fertil, 36, 557, 10.1016/j.gyobfe.2008.01.015 Clavel-Chapelon, 1997, E3N, a French cohort study on cancer risk factors. E3N Group. Étude épidemiologique auprès de femmes de l’Éducation nationale, Eur J Cancer Prev, 6, 473, 10.1097/00008469-199710000-00007 MWS Coll. Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. BJOG 2002;109:1319–30. Rodstrom, 1999, Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden, BMJ, 319, 890, 10.1136/bmj.319.7214.890 Vercambre, 2007, Differential dietary nutrient intake according to hormone replacement therapy use: an underestimated confounding factor in epidemiologic studies?, Am J Epidemiol, 166, 1451, 10.1093/aje/kwm162 Agence française de sécurité sanitaire des produits de santé (Afssaps). Traitement hormonal substitutif de la ménopause – Caractéristiques de l’utilisation en France. Effets sur la survenue de cancers du sein et d’évènements cardiovasculaires en France. Propositions d’études complémentaires, 2005. Available at: http://afssaps.sante.fr/. Du, 2005, Hormone replacement therapy in Germany: determinants and possible health-related outcomes. Results of National Health Surveys from 1984 to 1999, Maturitas, 52, 223, 10.1016/j.maturitas.2005.01.014 Austin, 2003, Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study, JAMA, 289, 3241, 10.1001/jama.289.24.3241 Hersh, 2004, National use of postmenopausal hormone therapy: annual trends and response to recent evidence, JAMA, 291, 47, 10.1001/jama.291.1.47 Ringa, 2004, Hormone therapy prescription among physicians in France and Quebec, Menopause, 11, 89, 10.1097/01.GME.0000072202.41124.1B Clavel-Chapelon, 1998, A validation study on status and age of natural menopause reported in the E3N cohort, Maturitas, 29, 99, 10.1016/S0378-5122(98)00020-6 Fabre, 2007, Oral progestagens before menopause and breast cancer risk, Br J Cancer, 96, 841, 10.1038/sj.bjc.6603618 Fabre, 2008, Progestagens use before menopause and breast cancer risk according to histology and hormone receptors, Cancer Epidemiol Biomarkers Prev, 17, 2723, 10.1158/1055-9965.EPI-08-0056 Poulter, 1999, Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications, Lancet, 354, 1610, 10.1016/S0140-6736(99)03132-3 Vasilakis, 1999, Risk of idiopathic venous thromboembolism in users of progestagens alone, Lancet, 354, 1610, 10.1016/S0140-6736(99)04394-9